关于我们

欧盟评估转基因紫红链霉菌菌株pCol生产的微生物胶原酶的安全性

放大字体  缩小字体 发布日期:2024-02-26  来源:食品伙伴网  作者:泽夕  浏览次数:95
核心提示:2024年2月23日,欧盟食品安全局就一种食品酶微生物胶原酶(microbial collagenase)的安全性评价发布意见。
   食品伙伴网讯  2024年2月23日,欧盟食品安全局就一种食品酶微生物胶原酶(microbial collagenase)的安全性评价发布意见。
 
  据了解,这种食品酶是由转基因紫红链霉菌菌株pCol生产的,旨在用于生产改良的肉类和鱼类产品以及从肉类和鱼类蛋白质中生产蛋白质水解产物。
 
  经过评估,专家小组认为,在预期的使用条件下,不能排除通过饮食接触引起过敏反应的风险,但这种情况发生的可能性很低。根据所提供的数据,小组得出结论,该食品酶在预期的使用条件下不会引起安全问题。部分原文报道如下:
 
  The food enzyme microbial collagenase (EC 3.4.24.3) is produced with the genetically modified Streptomyces violaceoruber strain pCol by Nagase (Europa) GmbH. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and its DNA. It is intended to be used in two food manufacturing processes: the production of modified meat and fish products and the production of protein hydrolysates from meat and fish proteins. The dietary exposure to the food enzyme–total organic solids (TOS) was estimated to be up to 1.098 mg TOS/kg body weight (bw) per day in European populations. Genotoxicity tests did not indicate a safety concern. The systemic toxicity was assessed by means of a repeated dose 90-day oral toxicity study in rats. The Panel identified a no observed adverse effect level of 940 mg TOS/kg bw per day, the highest dose tested, which, when compared with the estimated dietary exposure, resulted in a margin of exposure of at least 856. A search for the similarity of the amino acid sequence of the food enzyme to known allergens was made and no match was found. The Panel considered that the risk of allergic reactions by dietary exposure cannot be excluded, but the likelihood is low. based on the data provided, the Panel concluded that this food enzyme does not give rise to safety concerns, under the intended conditions of use.
 
  本文由食品伙伴网食品资讯中心编辑,供网友参考,有任何疑问,请联系news@foodmate.net。
 
 

农业生物技术科普平台

电话:(010)68869850/(0535)6736261

QQ:3112742182

邮箱:media@foodmate.net

鲁公网安备 37060202000936号